Partner booster session after hepatitis C care in people injecting drugs
Tests a booster session after hepatitis C treatment for drug injectors.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Registry title
- Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
- Status
- Not yet recruiting
- People taking part
- 50 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Treatments tested
- Partner navigation intervention booster session
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who inject drugs and recently finished hepatitis C (HCV) treatment, together with their main injecting partner.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Main participants must have a history of injecting drugs. Their partners must be the main injecting partner of an enrolled participant.
- Earlier treatment
- Main participants must have finished HCV treatment within the past 3 months.
Main reasons for not taking part
- Not able to give informed consent because of memory or thinking problems.
- Too intoxicated at enrolment to give informed consent.
- Took part in this study before in any role.
- Main participants: no main injecting partner willing to take part.
- Does not speak English or Spanish.
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- For index participants:
- 18 years of age or older at enrollment
- History of injecting drug use
- Completed HCV treatment within the past 3 months
- Report a primary injecting partner willing to participate
- Willing and able to provide informed consent
- English or Spanish speaking; For primary injecting partners:
- Primary injecting partner of an enrolled index participant:
- 18 years of age or older at enrollment
- Willing and able to provide informed consent
- English or Spanish speaking
- has context menu
Who cannot take part
- Previously participated in this study in any capacity
- Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment
- For both index participants and injecting partners:
Where in United States
- Quaker Meeting HouseSan Francisco, United StatesContact: Morris Meghan, PhDNot yet recruiting
About the trial
What the trial wants to find out
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject drugs (PWID) and their injecting partners in San Francisco. The proposed research includes secondary analyses of existing trial data, additional survey measures, qualitative interviews, and a pilot intervention adaptation.
Read full original descriptionShow less
The study has two primary objectives. First, it examines how racialized discrimination (structural, interpersonal, and internalized) affects HCV treatment initiation and dyadic partner support processes within injecting partnerships. Second, it evaluates whether a brief, adapted "booster" partner navigation session delivered at HCV treatment completion can improve engagement in ongoing healthcare.
Participants include adults (≥18 years) who inject drugs and have been diagnosed with HCV, along with their primary injecting partners. Study activities include longitudinal surveys, qualitative interviews with a subset of participants, and a pilot intervention session with follow-up evaluation.
This research addresses critical gaps in understanding how social relationships and structural inequities influence healthcare engagement among PWID. Findings will inform culturally responsive adaptations to dyadic interventions and improve continuity of care in a population disproportionately affected by HCV and systemic barriers to healthcare.
The group in the trial
- Partner Navigation Booster SessionTreatment being tested
Injecting dyads (index participant and their primary injecting partner) receive one adapted Partner Navigation Intervention booster session at the point of HCV treatment completion, designed to strengthen partnership-based support for sustained healthcare engagement beyond HCV care.
Treatment: Partner navigation intervention booster session
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
- Plain-language title
- Partner booster session after hepatitis C care in people injecting drugsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 8 June 2026